Thermo Fisher stock gains on UBS upgrade and solid Q2 growth
Published on 09/11/2026 at 11:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Thermo Fisher Scientific Inc. stock (ISIN US8835561023) is trading close to the 600-dollar mark after a series of recent analyst calls and solid second-quarter 2026 results highlighted mid-single-digit organic growth and a wider range of upside scenarios as of September 9, 2026.
UBS and CLSA lift expectations
According to Ad-hoc-news citing a report by TheStreet on September 10, 2026, UBS upgraded Thermo Fisher Scientific from Neutral to Buy on September 9, 2026 and raised its price target by 190 dollars, from 540 dollars to 730 dollars, placing the new target about 20 percent above the share price near 606 dollars on that day.
The same Ad-hoc-news article notes that the average 12-month target across 29 analysts is around 638 dollars, meaning the UBS target stands roughly 92 dollars above that consensus and underscores a more optimistic stance on the company’s ability to sustain mid-single-digit organic revenue growth as funding in biotech and bioprocessing improves.
Complementing this move, a blog analysis on Tikr on September 11, 2026 highlights that Thermo Fisher received two bullish reports within a week, with CLSA initiating coverage on September 3, 2026 at an Outperform rating and a price target of 748 dollars and UBS following with its higher 730-dollar target, both published while the shares were trading near the top of their 52-week range.
Second-quarter 2026 figures show double-digit revenue growth
An analysis published in Chinese on September 11, 2026 by EBC reports that in the second quarter of 2026 Thermo Fisher generated revenue of 11.99 billion dollars, up 10 percent year over year, with organic revenue growth of 5 percent for the period.
The same EBC article states that GAAP diluted earnings per share in the second quarter of 2026 reached 4.68 dollars, an increase of 9 percent compared with the prior year’s quarter, while adjusted EPS came in at 6.03 dollars, up 13 percent year over year, indicating that profitability improved faster than headline revenue.
According to EBC, analysts’ data show an average target price of about 645 dollars for Thermo Fisher stock, with the highest target at 750 dollars and the lowest at 520 dollars, and an overall rating of Buy, which suggests that the consensus upside of roughly 7 percent from a share price around 603 dollars is more moderate than the upside implied by the UBS and CLSA calls.
Share price near the upper end of the 52-week range
The EBC analysis notes that Thermo Fisher shares reached an intraday 52-week high on August 25, 2026 and subsequently entered a consolidation phase, with the stock oscillating around the 600-dollar level and briefly returning to roughly 618 dollars in early September before easing back toward 600 dollars.
In its snapshot as of September 11, 2026, EBC describes Thermo Fisher’s stock as fluctuating near 600 dollars, with the 600-dollar area seen as an important support zone after the earlier rally and the test of the 52-week high, suggesting that the market is now digesting the strong second-quarter numbers and recent analyst upgrades.
Separate coverage of Wall Street commentary by Tikr indicates that Thermo Fisher closed at 605.69 dollars on September 9, 2026, with a modest 0.44 percent gain on that day, even as price targets of 730 and 748 dollars from UBS and CLSA imply upside of roughly 20 percent or more relative to that closing level, showing that investors have so far reacted cautiously to the more aggressive scenarios.
Analyst consensus and Bernstein’s cautious stance
While UBS and CLSA have set ambitious targets, other houses remain more restrained: as The Globe and Mail reported on September 10, 2026, Bernstein analyst Eve Burstein reaffirmed a Hold rating on Thermo Fisher and set a price target of 575 dollars, which sits noticeably below the consensus target of about 641.06 dollars cited in that note.
MarketBeat’s analyst survey, referenced in a filing alert on September 11, 2026, shows that Thermo Fisher currently carries a Moderate Buy consensus rating, with two analysts assigning Strong Buy ratings, seventeen issuing Buy ratings, five rating the shares Hold and two recommending Sell, and an average target price of 624.64 dollars, underscoring that the overall Street view is positive but not uniformly bullish.
For investors, the key takeaway is that while average targets in the mid-620 to mid-640-dollar range point to single-digit percentage upside from prices around 603 to 606 dollars, outliers like UBS at 730 dollars and CLSA at 748 dollars define a higher-risk, higher-reward scenario that depends on Thermo Fisher continuing to deliver mid-single-digit organic growth and sustaining margin expansion.
Next test: third-quarter 2026 results
The Tikr analysis highlights that the next major catalyst for Thermo Fisher stock will be the third-quarter 2026 earnings report, expected in late October 2026, with management guidance pointing to organic revenue growth of around 4 percent for the second half of 2026, which will be closely watched as a validation or challenge to the bullish targets.
In that context, Tikr notes that if actual third-quarter data meet or exceed the roughly 4 percent organic growth guidance and metrics such as clinical research authorizations continue to improve, it would support UBS’s thesis that Thermo Fisher can grow even without a strong recovery in academic and government funding, whereas growth below that threshold could suggest that the share price has moved ahead of fundamentals.
Analyst commentary compiled by EBC and other portals therefore frames the current 600-dollar region as a tactical decision point: the stock has already priced in a significant portion of the recovery in earnings and the recent upgrades, but the extent to which the company can sustain 5 percent organic revenue growth and double-digit adjusted EPS growth beyond the second quarter will determine whether targets above 700 dollars are achievable.
Stock price and investor perspective
As of September 9, 2026, Thermo Fisher Scientific stock closed at 605.69 dollars on the New York Stock Exchange, with the price hovering close to its 52-week high that was tested intraday on August 25, 2026, which leaves limited room to the average Street target near the mid-620-dollar range but more substantial potential relative to the UBS and CLSA targets above 700 dollars.
Thermo Fisher Scientific stock facts
- Company: Thermo Fisher Scientific Inc.
- ISIN: US8835561023
- Ticker: TMO
- Trading venue: NYSE
- Price (as of September 9, 2026): 605.69 USD
- Sector / Industry: Health Care / Life Sciences Tools and Services
- Index membership: S&P 500
